Insights

Insight
February 2025

Advancing Rare Disease Care: Challenges and Key Issues

Insight
February 2025

EQ-5D and beyond: OHE’s contributions to EuroQol research and meetings

Insight
February 2025

Driving Green Change: Lessons from the 2024 Innovation Policy Prize

Insight
January 2025

Infectious disease: another reason to try Veganuary for the NHS

Insight
December 2024

OHE’s submission for the DHSC’s next 10 years of planning

Insight
November 2024

Latest estimates show that 20 people a day die in unrelieved pain across the UK at the end of their lives

Insight
November 2024

What is the impact of Uniform Pricing, Indication-Based Pricing (IBP) and alternative commercial arrangements for new pharmaceuticals in the UK NHS?

Insight
November 2024

Is collaboration between and across regulatory and HTA agencies the answer to access challenges?

Insight
October 2024

The Preventive Health Revolution: Insights from the 2024 Annual Lecture

A close-up image of a collection of orange prescription bottles neatly aligned in rows, with white caps and blank labels, against a white background. The repetitive pattern and bright color highlight the pharmaceutical industry’s mass production of medication.

Insight
September 2024

Drug shortages are on the rise – but what is their impact?

A man standing on one side of a chasm and the globe is on the other side.

Insight
September 2024

Green Healthcare: Are We Asking the Right Questions?

A hot air balloon flying in the colour of Thailand's flag flying above a land crossed by the river in Thailand

Insight
September 2024

Around The World in HTAs: Thailand – An Ever-Evolving Policy Tool

Newsroom

The latest news and comment from OHE experts

Read Now

Subscribe To Our Newsletter

Our monthly Bulletin highlights our work alongside the latest from across health economics and health care.

News and Insights

Latest Research & Publications

Valuing EQ-5D-Y Health States Using a Discrete Choice Experiment: Do Adult and Adolescent Preferences Differ?

Documento de debate sobre la fijación de precios en función de la indicación (IBP) ¿Deben variar los precios de los medicamentos según la indicación?

Indication-Based Pricing (IBP) Discussion Paper: Should drug prices differ by indication?

The WHO Technical Report on the Pricing of Cancer Medicines: Missing a central role for HTA and value assessment

Can We Really Compare and Aggregate PRO Data Between People and Settings? Implications for Multi-Country Clinical Trials and HTA

The Future of Global Health Procurement: Issues around Pricing Transparency

How Should We Measure Quality of Life Impact in Rare Disease? Recent Learnings in Spinal Muscular Atrophy

Exploring Variations in the Opportunity Cost Cost-effectiveness Threshold by Clinical Area: Results from a Feasibility Study in England

All Publications

Filter results by

Around The World in HTAs: Thailand – An Ever-Evolving Policy Tool

R&D For New Drugs To Tackle AMR Is A High Return Investment For All EU Member States

Filter results by

Advancing Rare Disease Care: Challenges and Key Issues

EQ-5D and beyond: OHE’s contributions to EuroQol research and meetings

Driving Green Change: Lessons from the 2024 Innovation Policy Prize

Infectious disease: another reason to try Veganuary for the NHS

OHE’s submission for the DHSC’s next 10 years of planning

Latest estimates show that 20 people a day die in unrelieved pain across the UK at the end of their lives

What is the impact of Uniform Pricing, Indication-Based Pricing (IBP) and alternative commercial arrangements for new pharmaceuticals in the UK NHS?

Is collaboration between and across regulatory and HTA agencies the answer to access challenges?

The Preventive Health Revolution: Insights from the 2024 Annual Lecture

Drug shortages are on the rise – but what is their impact?

Green Healthcare: Are We Asking the Right Questions?

Around The World in HTAs: Thailand – An Ever-Evolving Policy Tool

Newsroom

Subscribe To Our Newsletter

Share on Mastodon